Patents by Inventor Toni Beth Kline

Toni Beth Kline has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120034246
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: April 19, 2011
    Publication date: February 9, 2012
    Applicant: SEATTLE GENETICS, INC.
    Inventors: SVETLANA O. DORONINA, PETER D. SENTER, BRIAN E. TOKI, ALLEN J. EBENS, TONI BETH KLINE, PAUL POLAKIS, MARK X. SLIWKOWSKI, SUSAN D. SPENCER
  • Publication number: 20120027784
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 2, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20120027783
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 2, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: SVETLANA O. DORONINA, PETER D. SENTER, BRIAN E. TOKI, ALLEN J. EBENS, TONI BETH KLINE, PAUL POLAKIS, MARK X. SLIWKOWSKI, SUSAN D. SPENCER
  • Publication number: 20120003248
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: April 29, 2011
    Publication date: January 5, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Patent number: 7994135
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: August 9, 2011
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Patent number: 7964567
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: June 21, 2011
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Patent number: 7964566
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: June 21, 2011
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Patent number: 7745394
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: June 29, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20090111756
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 7, 2006
    Publication date: April 30, 2009
    Applicant: Seattle Genectics, Inc.
    Inventors: Svetlana O. Doronina, Toni Beth Kline, Scott Jeffrey, Peter D. Senter, Damon Meyer
  • Publication number: 20090047296
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 19, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20090018086
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.
    Type: Application
    Filed: July 7, 2006
    Publication date: January 15, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Toni Beth Kline
  • Publication number: 20080248051
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: August 3, 2007
    Publication date: October 9, 2008
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20080248053
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: August 3, 2007
    Publication date: October 9, 2008
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20080226657
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: August 3, 2007
    Publication date: September 18, 2008
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer